Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seen And Heard: Congressional Investigator Slams FDA Office Of Chief Counsel On Heparin Case

This article was originally published in PharmAsia News

Executive Summary

A senior investigator for the House Energy and Commerce Committee testified at an April 29 hearing that FDA's Office of Chief Counsel had thwarted a congressional investigation into heparin contamination in China. David Nelson said the OCC refused to provide documents relating to FDA's inspection process and would not let investigators interview OCC staff attorneys
Advertisement

Related Content

U.S. FDA’s Poor Performance ‘Invites Catastrophe’ – U.S. Congressional Committee On Heparin Investigation
U.S. FDA’s Poor Performance ‘Invites Catastrophe’ – U.S. Congressional Committee On Heparin Investigation
Advertisement
UsernamePublicRestriction

Register

SC068512

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel